Progress in the development of naturally derived active metabolites‐based drugs: Potential therapeutics for Alzheimer's disease.
Saved in:
| Title: | Progress in the development of naturally derived active metabolites‐based drugs: Potential therapeutics for Alzheimer's disease. |
|---|---|
| Authors: | Mani, Renuka1 (AUTHOR), sha Sulthana, Ahmed1 (AUTHOR), Muthusamy, Ganesan2 (AUTHOR), Elangovan, Namasivayam1 (AUTHOR) elangovannn@gmail.com |
| Source: | Biotechnology & Applied Biochemistry. Dec2022, Vol. 69 Issue 6, p2713-2732. 20p. |
| Subjects: | Alzheimer's disease, Successful aging, Neurodegeneration, Natural products, Therapeutics |
| Abstract: | Alzheimer's disease (AD) is an extensive age‐associated neurodegenerative disorder. In spite of wide‐ranging progress in understanding the AD pathology for the past 50 years, clinical trials based on the hypothesis of amyloid‐beta (Aβ) have reserved worsening particularly at late‐stage human trials. Consequently, very few old drugs are presently used for AD with inadequate clinical consequences and various side effects. We focus on widespread pharmacological and beneficial principles for existing as well as future drugs. Multitargeting approaches by means of general antioxidant and anti‐inflammatory mechanisms allied with particular receptor and/or enzyme‐mediated actions in neuroprotection and neurodegeneration. The plant kingdom comprises a vast range of species with an incredible diversity of bioactive metabolites with diverse chemical scaffolds. In recent times, an increasing body of facts recommended the use of phytochemicals to decelerate AD's onset and progression. The definitive goal of AD investigation is to avert the onset of neurodegeneration, thereby allowing successful aging devoid of cognitive decline. At this point, we discussed the neurological protective role of natural products and naturally derived therapeutic agents for AD from various natural polyphenolic compounds and medicinal plants. In conclusion, medicinal plants act as a chief source of different bioactive constituents. [ABSTRACT FROM AUTHOR] |
| Copyright of Biotechnology & Applied Biochemistry is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: egs DbLabel: Engineering Source An: 160965011 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Progress in the development of naturally derived active metabolites‐based drugs: Potential therapeutics for Alzheimer's disease. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Mani%2C+Renuka%22">Mani, Renuka</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22sha+Sulthana%2C+Ahmed%22">sha Sulthana, Ahmed</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Muthusamy%2C+Ganesan%22">Muthusamy, Ganesan</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Elangovan%2C+Namasivayam%22">Elangovan, Namasivayam</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> elangovannn@gmail.com</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Biotechnology+%26+Applied+Biochemistry%22">Biotechnology & Applied Biochemistry</searchLink>. Dec2022, Vol. 69 Issue 6, p2713-2732. 20p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Alzheimer's+disease%22">Alzheimer's disease</searchLink><br /><searchLink fieldCode="DE" term="%22Successful+aging%22">Successful aging</searchLink><br /><searchLink fieldCode="DE" term="%22Neurodegeneration%22">Neurodegeneration</searchLink><br /><searchLink fieldCode="DE" term="%22Natural+products%22">Natural products</searchLink><br /><searchLink fieldCode="DE" term="%22Therapeutics%22">Therapeutics</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Alzheimer's disease (AD) is an extensive age‐associated neurodegenerative disorder. In spite of wide‐ranging progress in understanding the AD pathology for the past 50 years, clinical trials based on the hypothesis of amyloid‐beta (Aβ) have reserved worsening particularly at late‐stage human trials. Consequently, very few old drugs are presently used for AD with inadequate clinical consequences and various side effects. We focus on widespread pharmacological and beneficial principles for existing as well as future drugs. Multitargeting approaches by means of general antioxidant and anti‐inflammatory mechanisms allied with particular receptor and/or enzyme‐mediated actions in neuroprotection and neurodegeneration. The plant kingdom comprises a vast range of species with an incredible diversity of bioactive metabolites with diverse chemical scaffolds. In recent times, an increasing body of facts recommended the use of phytochemicals to decelerate AD's onset and progression. The definitive goal of AD investigation is to avert the onset of neurodegeneration, thereby allowing successful aging devoid of cognitive decline. At this point, we discussed the neurological protective role of natural products and naturally derived therapeutic agents for AD from various natural polyphenolic compounds and medicinal plants. In conclusion, medicinal plants act as a chief source of different bioactive constituents. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Biotechnology & Applied Biochemistry is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=160965011 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/bab.2317 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 20 StartPage: 2713 Subjects: – SubjectFull: Alzheimer's disease Type: general – SubjectFull: Successful aging Type: general – SubjectFull: Neurodegeneration Type: general – SubjectFull: Natural products Type: general – SubjectFull: Therapeutics Type: general Titles: – TitleFull: Progress in the development of naturally derived active metabolites‐based drugs: Potential therapeutics for Alzheimer's disease. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Mani, Renuka – PersonEntity: Name: NameFull: sha Sulthana, Ahmed – PersonEntity: Name: NameFull: Muthusamy, Ganesan – PersonEntity: Name: NameFull: Elangovan, Namasivayam IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: Dec2022 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 08854513 Numbering: – Type: volume Value: 69 – Type: issue Value: 6 Titles: – TitleFull: Biotechnology & Applied Biochemistry Type: main |
| ResultId | 1 |
